Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

In-Jin Jang

Showing results (111-120 of 292) with videos related to

Pageof 30
Sort By:
Drug Design, Development and Therapy|April 20, 2023
Pharmacokinetics and Pharmacodynamics of Esomezol DR, a New Dual Delayed-Release Formulation of Esomeprazole 20 Mg or 40 Mg, in Healthy SubjectsHyun Chul Kim, Eunsol Yang, Mu Seong Ban, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|December 31, 2002
Simple and sensitive determination of the new antitumor drug CKD-602 in human plasma by liquid chromatographyJoo Youn Cho, Hyo Bum Seo, Kyung Sang Yu, et al.
Clinical Therapeutics|November 1, 2011
Pharmacokinetic comparison of a new sustained-release formulation of glimepiride/metformin 1/500 mg combination tablet and a sustained-release formulation of glimepiride/metformin 2/500 mg combination tablet in healthy Korean male volunteers: a randomized, 2-sequence, 2-period, 2-treatment crossover studyKwang-Hee Shin, Sung Eun Kim, Seo Hyun Yoon, et al.
Drug Design, Development and Therapy|January 29, 2014
Comparative steady-state pharmacokinetic study of an extended-release formulation of itopride and its immediate-release reference formulation in healthy volunteersSeonghae Yoon, Howard Lee, Tae-Eun Kim, et al.
Drug Design, Development and Therapy|May 6, 2021
Comparison of Pharmacokinetic, Pharmacodynamic and Tolerability Profiles of CKD-11101, Darbepoetin Alfa (NESP<sup>®</sup>) Biosimilar, to Those of NESP<sup>®</sup> After a Single Subcutaneous or Intravenous Administration to Healthy SubjectsInseung Jeon, Jaeseong Oh, Yu-Kyung Kwon, et al.
Diabetes Research and Clinical Practice|July 30, 2021
Changes in the gut microbiome influence the hypoglycemic effect of metformin through the altered metabolism of branched-chain and nonessential amino acidsYujin Lee, Andrew HyoungJin Kim, Eunwoo Kim, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 24, 2004
Haplotype structure and allele frequencies of CYP2B6 in a Korean populationJoo-Youn Cho, Hyeong-Seok Lim, Jae-Yong Chung, et al.
The AAPS Journal|May 20, 2017
Distribution of Exogenous and Endogenous CYP3A Markers and Related Factors in Healthy Males and FemalesJieon Lee, Andrew HyoungJin Kim, SoJeong Yi, et al.
Plos One|April 25, 2017
The novel carboxylesterase 1 variant c.662A>G may decrease the bioactivation of oseltamivir in humansJaeseong Oh, SeungHwan Lee, Howard Lee, et al.
International Journal of Clinical Pharmacology and Therapeutics|April 14, 2017
Pharmacokinetic comparison using two tablets of an evogliptin/metformin XR 2.5/500 mg fixed dose combination vs. 1 tablet each of evogliptin 5 mg and metformin XR 1,000 mg
Sumin Yoon, Su-Jin Rhee, Sang-In Park, et al.
Pageof 30

Showing results (111-120 of 292) with videos related to

Sort By:
Pageof 30
Drug Design, Development and Therapy|April 20, 2023
Pharmacokinetics and Pharmacodynamics of Esomezol DR, a New Dual Delayed-Release Formulation of Esomeprazole 20 Mg or 40 Mg, in Healthy SubjectsHyun Chul Kim, Eunsol Yang, Mu Seong Ban, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|December 31, 2002
Simple and sensitive determination of the new antitumor drug CKD-602 in human plasma by liquid chromatographyJoo Youn Cho, Hyo Bum Seo, Kyung Sang Yu, et al.
Clinical Therapeutics|November 1, 2011
Pharmacokinetic comparison of a new sustained-release formulation of glimepiride/metformin 1/500 mg combination tablet and a sustained-release formulation of glimepiride/metformin 2/500 mg combination tablet in healthy Korean male volunteers: a randomized, 2-sequence, 2-period, 2-treatment crossover studyKwang-Hee Shin, Sung Eun Kim, Seo Hyun Yoon, et al.
Drug Design, Development and Therapy|January 29, 2014
Comparative steady-state pharmacokinetic study of an extended-release formulation of itopride and its immediate-release reference formulation in healthy volunteersSeonghae Yoon, Howard Lee, Tae-Eun Kim, et al.
Drug Design, Development and Therapy|May 6, 2021
Comparison of Pharmacokinetic, Pharmacodynamic and Tolerability Profiles of CKD-11101, Darbepoetin Alfa (NESP<sup>®</sup>) Biosimilar, to Those of NESP<sup>®</sup> After a Single Subcutaneous or Intravenous Administration to Healthy SubjectsInseung Jeon, Jaeseong Oh, Yu-Kyung Kwon, et al.
Diabetes Research and Clinical Practice|July 30, 2021
Changes in the gut microbiome influence the hypoglycemic effect of metformin through the altered metabolism of branched-chain and nonessential amino acidsYujin Lee, Andrew HyoungJin Kim, Eunwoo Kim, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 24, 2004
Haplotype structure and allele frequencies of CYP2B6 in a Korean populationJoo-Youn Cho, Hyeong-Seok Lim, Jae-Yong Chung, et al.
The AAPS Journal|May 20, 2017
Distribution of Exogenous and Endogenous CYP3A Markers and Related Factors in Healthy Males and FemalesJieon Lee, Andrew HyoungJin Kim, SoJeong Yi, et al.
Plos One|April 25, 2017
The novel carboxylesterase 1 variant c.662A>G may decrease the bioactivation of oseltamivir in humansJaeseong Oh, SeungHwan Lee, Howard Lee, et al.
International Journal of Clinical Pharmacology and Therapeutics|April 14, 2017
Pharmacokinetic comparison using two tablets of an evogliptin/metformin XR 2.5/500 mg fixed dose combination vs. 1 tablet each of evogliptin 5 mg and metformin XR 1,000 mg
Sumin Yoon, Su-Jin Rhee, Sang-In Park, et al.
Pageof 30